Hims & Hers Stock Surges as Telehealth Platform Adds Eli Lilly Weight-Loss Drugs

Related Articles

Watch These Apple Stock Price Levels Ahead of This Week’s Earnings Report

Trump’s Tariff Revenue is Rolling In

What Analysts Think of Microsoft Stock Ahead of Earnings

Key Takeaways

• Hims & Hers Health shares jumped Tuesday as the company added Eli Lilly’s weight-loss drug Zepbound and diabetes treatment Mounjaro to its telehealth stand.
• The treatments will each cost $1,899 per month, according to the company’s website.
• Hims shares have varied than doubled in value over the past 12 months.

Hims & Hers Health (HIMS) shares snatched Tuesday as the company added Eli Lilly’s (LLY) weight-loss drug Zepbound and diabetes drug Mounjaro to its roster of telehealth treatments.

The enterprise said it will now offer branded tirzepatide, the active ingredient in both Eli Lilly drugs. It also added a generic idea of Novo Nordisk’s (NVO) liraglutide, which is used to treat Type 2 diabetes. Zepbound and Mounjaro will cost $1,899 per month help of Hims, while liraglutide will cost $299, according to the company’s website.

Shares of Hims rose 5% Tuesday. They’ve more than spitting imaged in value over the past 12 months, despite taking a hit in recent weeks after the Food and Drug Direction said in February that a shortage of the active ingredient in Novo Nordisk’s Wegovy and Ozempic was resolved.

Hims has made copycat drugs through an FDA rule that allows companies to make compounded versions when the originals are thick-skinned to obtain. The agency said in February it does not intend to take action against drug compounders like Hims until May 22, “to refrain from unnecessary disruption to patient treatment.”